PDCD1 and non-small cell lung carcinoma: Nivolumab and pembrolizumab (anti-PD-1 antibodies) as well as atezolizumab and durvalumab (anti-PD-L1 antibody) are used in monotherapy in the first- and the second-line therapy in advanced NSCLC patients.